Neurocrine Biosciences Announces Top-Line Results from Phase

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

, Neurocrine Biosciences , Negative Symptoms , Neurocrine , Investigational Drug , Negative Outcome , Cognitive Assessment , Development , Clinical Study , Primary Endpoint , எதிர்மறை அறிகுறிகள் , எதிர்மறை ஔட்‌கம் , அறிவாற்றல் மதிப்பீடு , வளர்ச்சி , மருத்துவ படிப்பு , ப்ரைமரீ இறுதிப்புள்ளி ,